Abstract:It is well accepted that the balance of immunity between effector and regulatory T cells determines the outcome of autoimmune and chronic inflammatory diseases. Concerning the topic of ‘Regulatory and Effector T Cells’ as published in this issue of Journal of Molecular Cell Biology, several investigators have provided important new information. T-helper 1 (Th1) and Th2 cells represent the classical type of Th or effector cells. However, recent studies have also identified several new cell subsets of Th cells, including IL-9-producing T (Th9), IL-17-producing T (Th17), IL-22-producing T (Th22), and T follicular helper (Tfh) cells, extending the Th cell structure. Given their crucial role in the pathogenesis of autoimmune and inflammatory diseases, Th17 cells have received much attention. They mainly express IL-17A, but co-express IL-17B, IL-17E (IL-25), IL-17F, and IL-22. IL-26 is produced by human but not mouse Th17 cells. IL-17A is significantly more potent in initiating signaling and causing autoimmune responses than other cytokines produced by these cells. The differentiation of mouse Th17 cells needs the combination of IL-6 and transforming growth factor-beta (TGF-b) (Bettelli et al., 2006), although IL-6or TGF-b-independent pathways may also contribute to Th17 cell differentiation. The role of TGF-b in human Th17 cell differentiation is still controversial. Of note, the IL-21 and IL-1 signal pathways seem to be important in initiating Th17 cell development. IL-21 and IL-23 are also known to sustain and expand Th17 cells. Dr Ryffel’s group provides an updated account of the differentiation and function of Th17 cells, particularly during lung injury and inflammatory disease. They demonstrated that lung injury or allergen exposure leads to NLPR3 activation, with formation of the NLPR3 inflammasome complex and caspase-1 activation resulting in mature IL-1b, which may elicit IL-17 production. Traditionally, asthma is elicited by Th2 cells. It is still unclear whether Th17 cells work independent or together with Th2 cells in the development of asthma. They suggest that Th17 cells promote asthma through modulation of Th2 cells. In fact, IL-17E or IL-25, another IL-17 member, can induce Th2 cytokines and promote allergy. It is also possible that IL-17 regulates allergic responses independent of Th2 cells but Th2 cells promote asthma through Th17 cells since IL-4 does regulate IL-17 levels. It has been widely accepted that Tregs are critically involved in immune tolerance and homeostasis. Although this concept was suggested in early 1970s, it was resuscitated in 1990s when thymus-derived CD4+CD25+ cells were identified as natural Tregs (nTregs) (Sakaguchi et al., 1995). While Foxp3 has been identified as a unique marker and functional transcription factor for these cells, studies on Tregs have been greatly accelerated. As Treg frequency and functional alterations are associated with many autoimmune diseases, the manipulation of these cells provides a promising treatment possibility for autoimmune diseases. In addition, use of Tregs may be valuable in the prevention of graft rejection of organ transplantation and graft-versus-host disease (GVHD). Dr Bluestone’s group further provides information on the potential use of these cells in the clinic. They reported that by 2011, three clinical trials have been undertaken to test the safety of Treg therapy in GVHD, and all have demonstrated promising safety and efficacy profiles. Compelling evidence from animal models and human patients demonstrates that tolerance to allogeneic transplant can be achieved by reconditioning the immune system, so that troublesome global immunosuppression can be minimized or completely stopped. They emphasize that a sound trial design should harness the tolerogenic potential of Tregs while minimizing risks. One potential risk with Treg therapy is that these cells can purportedly exhibit some measure of plasticity. Since little is known about the appropriate doses of Tregs in humans, initial trials should be safety-centered evaluating effect of increasing

Targeting the B7 Family of Co-Stimulatory Molecules

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Engagement of B7 on Effector T Cells by Regulatory T Cells Prevents Autoimmune Disease.

Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity

New Immunotherapies Targeting the PD-1 Pathway.

New Immunotherapies Targeting The Pd-1 Pathway

Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis

Targeting Th17 Cells with Small Molecules and Small Interference RNA

Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies

Targeting Cbl-b in cancer immunotherapy

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

The Third Group Of The B7-Cd28 Immune Checkpoint Family: Hhla2, Tmigd2, B7x, And B7-H3

Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System

[The Identical Effects of B7-1 and B7-2 on Regulation of Human IL-2 Gene Transcription Factors NF-kappa B and AP-1].

The Role of the CD28 Family Receptors in T-Cell Immunomodulation

Emerging Topics and New Perspectives on Regulatory and Effector T Cells.

Disrupting B and T cell Collaboration in Autoimmune Disease: T cell engagers versus CAR T cell therapy?

The balance of immune responses: costimulation verse coinhibition

Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases